Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 3Sarcoma, Kaposi 2Melanoma 2HIV Infections 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Head and Neck Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 24Nivolumab 9atezolizumab 8Drug Therapy 6cemiplimab 5Immune Checkpoint Inhibitors 5fludarabine 4Radiotherapy 4Paclitaxel 4Interleukin-2 4Cyclophosphamide 4Docetaxel 3fludarabine phosphate 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Radiation 2Patient Reported Outcome Measures 2Oncolytic Virotherapy 2Ipilimumab 2Immunotherapy 2Gemcitabine 2Filgrastim 2Cisplatin 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Semaxinib × Dermatologic × Clear all
NCT00006361 2009-12-04

SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡